Serum connective tissue markers as predictors of advanced fibrosis in patients with chronic hepatitis B and D

Turkish Journal of Gastroenterology

Volumn 22, Issue 3, 2011, Pages 305-314

  Seven, Gülseren ^a   Karatayli, Senem Ceren ^a   Köse, S Kenan ^a   Yakut, Mustafa ^a   Kabaçam, Gökhan ^a   Törüner, Murat ^a   Okçu Heper, Aylin ^a   Voelker, Michael ^b   Erden, Esra ^a   Bozdayi, A Mithat ^a   Uzunalimoǧlu, Özden ^a   Bozkaya, Hakan ^a   Yurdaydin, Cihan ^a   Schuppan, Detlef ^c  

^a ANKARA UNIVERSITY   (Turkey)

^b BAYER AG   (Germany)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Collagen; Grade; Hyaluronan; Laminin; Matrix metalloproteinase; Metavir; Platelets; Procollagen; Progression; Stage; Tissue inhibitor of metalloproteinases 1

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; COLLAGEN TYPE 4; COLLAGEN TYPE 6; GAMMA GLUTAMYLTRANSFERASE; GELATINASE A; GELATINASE B; HYALURONIC ACID; LAMININ; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; TENASCIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; DELTA AGENT HEPATITIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GOLD STANDARD; HEPATITIS B; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER FIBROSIS; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PROTHROMBIN TIME; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SPLENOMEGALY; THROMBOCYTE COUNT;

ADULT; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BIOPSY; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS D, CHRONIC; HUMANS; HYALURONIC ACID; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; LOGISTIC MODELS; MALE; PREDICTIVE VALUE OF TESTS; ROC CURVE; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 79961123125     PISSN: 13004948     EISSN: None     Source Type: Journal    
DOI: 10.4318/tjg.2011.0217     Document Type: Article

References (56)

1. Lok ASF, Heathcote EJ, Hoofnagle JH. Management of hepatitis B, 2000: summary of a workshop. Gastroenterology 2001; 120: 1828-53. (Pubitemid 32523500)
2. Heathcote J. Antiviral therapy for patients with chronic hepatitis C. Semin Liver Dis 2000; 20: 185-99. (Pubitemid 30623451)
3. Nord JH. Biopsy diagnosis of cirrhosis: blind percutaneous versus guided direct vision techniques. A review. Gastrointest Endosc 1982; 28: 102-4.
4. Abdi W, Millan JC, Mezey E. Sampling variability on percutaneous liver biopsy. Arch Intern Med 1974; 139: 667-9. (Pubitemid 10097795)
5. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-8.
6. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57. (Pubitemid 37466971)
7. Colombo M, Del Ninno E, De Franchis R, et al. Ultrasoundassisted percutaneous liver biopsy: superiority of the Trucut over the Menghini needle for diagnosis of cirrhosis. Gastroenterology 1988; 95: 487-9.
8. Pinzani M. The ELF panel: a new crystal ball in hepatology? Gut 2010; 59: 1165-7.
9. Rohde H, Vargas L, Hahn E, et al. Radioimmunoassay for type III procollagen peptide and its application to human liver disease. Eur J Clin Invest 1979; 9: 451-9. (Pubitemid 10214941)
10. Schuppan D, Stölzel U, Oesterling C, Somasundaram R. Serum assays for liver fibrosis. J Hepatol 1995; 22(Suppl): 82-8.
11. Poynard T, Aubert A, Bedossa P, et al. A simple biological index for detection of alcoholic liver disease in drinkers. Gastroenterology 1991; 100: 1397-402.
12. Naveau S, Poynard T, Benattar C, et al. Alpha-1-macroglobulin and hepatic fibrosis: diagnostic interest. Dig Dis Sci 1994; 11: 2426-32. (Pubitemid 24350026)
13. Poynard T, Bedossa P. Age and platelet count: a simple index for predicting the presence of histologic lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J Viral Hepat 1997; 4: 199-208. (Pubitemid 127733511)
14. Imbert-Bismut F, Ratziu V, Pieroni L, et al., for the MULTIVIRC group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-75. (Pubitemid 32322537)
15. Forns X, Ampurdanès S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-92.
16. Kaul V, Friedenberg FK, Braitman LE, et al. Development and validation of a model to diagnose cirrhosis in patients with hepatitis C. Am J Gastroenterol 2002; 97: 2623-8.
17. Wai C-T, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26. (Pubitemid 36919874)
18. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127: 1704-13. (Pubitemid 39575849)
19. Ropers T, Kroll W, Becka M, et al. Enzyme immunoassay for the measurement of human tenascin-C on the Bayer Immuno analyzer. Clin Biochem 1999; 33: 7-13. (Pubitemid 30313038)
20. Hanke B, Wein A, Martus B, et al. Serum markers of matrix turnover as predictors for the evolution of colorectal cancer metastasis under chemotherapy. Br J Cancer 2003; 88: 1248-50. (Pubitemid 36606341)
21. Lebensztejn DM, Kaczmarski M, Sobaniec-Lotowska M, et al. Serum laminin-2 and hyaluronan predict severe liver fibrosis in children with chronic hepatitis B. Hepatology 2004; 39: 868-9. (Pubitemid 38337673)
22. Yurdaydin C, Bozkaya H, Gürel S, et al. Famciclovir treatment of chronic delta hepatitis. J Hepatol 2002; 37: 266-71. (Pubitemid 34833090)
23. Yurdaydin C, Bozkaya H, fientürk H, et al. Treatment of chronic delta hepatitis with lamivudine vs. lamivudine+interferon vs. interferon. J Viral Hepat 2008; 15: 314-21. (Pubitemid 351326903)
24. Yurdaydin C, Bozkaya H, Çetinkaya H, et al. Lamivudine vs lamivudine and interferon combination treatment of HBeAg (-) chronic hepatitis B. J Viral Hepat 2005; 12: 262-8. (Pubitemid 40638033)
25. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretations in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20.
26. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2001; 34: 1225-41. (Pubitemid 33096596)
27. Yurdaydin C, Idilman R, Bozkaya H, Bozdayi AM. Natural history and treatment of chronic delta hepatitis. J Viral Hepat 2010; 17: 749-56.
28. Gaeta GB, Stroffolini T, Chiaramonte M, et al. Chronic hepatitis D: a vanishing disease? An Italian multicenter study. Hepatology 2000; 32: 824-7.
29. Deǧertekin H, Yalçin K, Yakut M, Yurdaydin C. Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta-analysis. Liver Int 2008; 28: 494-8. (Pubitemid 351411135)
30. Yurdaydin C. Delta hepatitis in Turkey: decreasing but not vanishing and still of concern. Turk J Gastroenterol 2006; 17: 74-5. (Pubitemid 46534959)
31. Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C infection. Am J Gastroenterol 1998; 93: 44-8. (Pubitemid 29065511)
32. Pohl A, Behling C, Oliver D, et al. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 2001; 96: 3142-4.
33. Friedman SL. Evaluation of fibrosis and hepatitis C. Am J Med 1999; 107: 27S-30S.
34. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. Lancet 1997; 349: 825-32. (Pubitemid 27129209)
35. Myers RP, Hilsden RJ, Lee SS. Historical features are poor predictors of liver fibrosis in Canadian patients with chronic hepatitis C. J Viral Hepat 2001; 8: 249-55. (Pubitemid 32673735)
36. Myers RP, Ratziu V, Imbert-Bismut F, et al. Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C. Am J Gastroenterol 2002; 97: 2419-25.
37. Oberti F, Valsesia E, Pilette C, et al. Non-invasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 1997; 113: 1609-16. (Pubitemid 27461247)
38. Myers RP, Tainturier M-H, Ratziu V, et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003; 39: 222-30. (Pubitemid 36920558)
39. Poynard T, Zoulim F, Ratziu V, et al. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol 2005; 100: 1970-80.
40. Sebastiani G, Vario A, Guido M, Alberti A. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol 2007; 13: 525-31. (Pubitemid 46210918)
41. McHutchison JG, Blatt LM, De Medina M, et al. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J Gastroenterol Hepatol 2000; 15: 945-51.
42. Guechot J, Laudat A, Loria A, et al. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem 1996; 42: 558-63. (Pubitemid 26111874)
43. Frébourg T, Delpech B, Bercoff E, et al. Serum hyaluronate in liver disease: study by enzymoimmunological assay. Hepatology 1986; 6: 392-5. (Pubitemid 16086624)
44. Gibson PR, Fraser JRE, Brown TJ, et al. Hemodynamic and liver function predictors of serum hyaluronate in alcoholic liver disease. Hepatology 1992; 15: 1054-9.
45. Valenti L, Dongiovanni P. Serum hyaluronic acid for the screening of progressive nonalcoholic steatohepatitis in children: a promising approach. Transl Res 2010; 156: 226-8.
46. Guéchot J, Poupon RE, Poupon R. Serum hyaluronan as a marker for liver fibrosis. J Hepatol 1995; 22(Suppl): 103-6.
47. Eriksson S, Fraser JR, Laurent TC, et al. Endothelial cells are a site of uptake and degradation of hyaluronic acid in the liver. Exp Cell Res 1983; 144: 223-8. (Pubitemid 13079334)
48. Fraser JR, Laurent TC, Laurent UB. Hyaluronan: its nature, distribution, functions and turnover. J Intern Med 1997; 242: 27-33. (Pubitemid 27323862)
49. Murphy G, Willenbrock F. Tissue inhibitors of matrix metalloproteinases. Method Enzymol 1995; 248: 496-510.
50. Iredale JP, Benyon RC, Pickering J, et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998; 102: 538-49. (Pubitemid 28376157)
51. Murawaki Y, Ikuta Y, Idobe Y, et al. Tissue inhibitor of metalloproteinase-1 in the liver of patients with chronic liver disease. J Hepatol 1997; 26: 1213-9. (Pubitemid 27346632)
52. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127: 1704-13. (Pubitemid 39575849)
53. Friedrich-Rust M, Rosenberg W, Parkes J, et al. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterol 2010; 10: 103.
54. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003; 39: 239-244. (Pubitemid 36920560)
55. Crawford AR, Lin XZ, Crawford JM. The normal adult human liver biopsy: a quantitative reference standard. Hepatology 1998; 28: 323-31. (Pubitemid 28363655)
56. Bravo AA, Sheth SG, Chopra S. Liver biopsy. New Engl J Med 2001; 344: 495-500. (Pubitemid 32164902)